At the time of writing, Actuate Therapeutics Inc [ACTU] stock is trading at $6.9, up 10.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACTU shares have gain 17.95% over the last week, with a monthly amount glided 1.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Actuate Therapeutics Inc [NASDAQ: ACTU] stock has seen the most recent analyst activity on August 26, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $20. Previously, Craig Hallum started tracking the stock with Buy rating on April 22, 2025, and set its price target to $21. On March 17, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $20 on the stock.
For the past year, the stock price of Actuate Therapeutics Inc fluctuated between $5.47 and $11.99. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Actuate Therapeutics Inc [NASDAQ: ACTU] shares were valued at $6.9 at the most recent close of the market. An investor can expect a potential return of 204.35% based on the average ACTU price forecast.
Analyzing the ACTU fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.36, Equity is -29.24 and Total Capital is -2.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.13 points at the first support level, and at 5.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.34, and for the 2nd resistance point, it is at 7.77.
Ratios To Look Out For
It is important to note that Actuate Therapeutics Inc [NASDAQ:ACTU] has a current ratio of 2.74. Further, the Quick Ratio stands at 2.74, while the Cash Ratio is 2.66.
Transactions by insiders
Recent insider trading involved Bios Equity COF, LP, Director, that happened on Jun 27 ’25 when 71428.0 shares were purchased. Director, Kreis Leslie W. completed a deal on Jun 27 ’25 to buy 71428.0 shares. Meanwhile, Director Fletcher Aaron G.L. bought 71428.0 shares on Jun 27 ’25.
